Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Abivax S.A.

Abivax S.A. (ABVX) Stock Overview

Explore Abivax S.A.’s financial performance, market position, analyst ratings, and future outlook.

ABVX●NASDAQ
HealthcareBiotechnology
$126.23
$2.72(2.18%)
U.S. Market is Open · 14:16

Abivax S.A. (ABVX)

Meyka AI Score

Z

Key Financials

Market Cap9.2B
P/E Ratio-29.43
EPS (TTM)$-1.91
ROE-1.65%
Fundamental Analysis

AI Price Forecasts

1 Month$136.86
3 Months$203.24
1 Year Target$156.80

ABVX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Abivax S.A. (NASDAQ: ABVX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Abivax S.A.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ABVX on the NASDAQ shows an RSI of 49.84, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $156.80 for the NASDAQ listing.

Key metrics behind Abivax S.A.'s NASDAQ-traded stock include a P/E ratio of -29.43 and a market capitalization of 9.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ABVX on the NASDAQ.

Price Performance (NASDAQ: ABVX)

1-Day Change
0.33%
5-Day Change
4.67%
1-Month Change
-13.06%
3-Month Change
6.88%
6-Month Change
10.23%
Year-to-Date (YTD) Change
-7.16%
1-Year Change
73.71%
3-Year Change
1408.31%
5-Year Change
1408.31%
All-Time (Max) Change
1408.31%

Contact Information

https://www.abivax.com
33 1 53 83 08 41
7-11 Boulevard Haussmann, Paris, IF, 75008

Company Facts

800 Employees
IPO DateOct 20, 2023
CountryFR
Actively Trading

Frequently Asked Questions